Toronto Dominion Bank raised its holdings in Edwards Lifesciences Corp (NYSE:EW) by 15.8% in the first quarter, Holdings Channel reports. The institutional investor owned 144,613 shares of the medical research company’s stock after acquiring an additional 19,735 shares during the quarter. Toronto Dominion Bank’s holdings in Edwards Lifesciences were worth $27,662,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. raised its position in Edwards Lifesciences by 7.4% during the fourth quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock valued at $2,516,802,000 after acquiring an additional 1,128,082 shares in the last quarter. Oregon Public Employees Retirement Fund raised its position in Edwards Lifesciences by 21,360.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 10,587,326 shares in the last quarter. FMR LLC raised its position in Edwards Lifesciences by 28.9% during the fourth quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock valued at $1,160,540,000 after acquiring an additional 1,700,199 shares in the last quarter. Jennison Associates LLC raised its position in Edwards Lifesciences by 184.7% during the fourth quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock valued at $629,855,000 after acquiring an additional 2,667,749 shares in the last quarter. Finally, Norges Bank purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $559,646,000. Institutional investors own 84.43% of the company’s stock.

Several brokerages recently weighed in on EW. Morgan Stanley lifted their price target on Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. BMO Capital Markets lifted their price target on Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Credit Suisse Group lifted their price target on Edwards Lifesciences from $189.00 to $221.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Barclays lifted their price target on Edwards Lifesciences from $150.00 to $160.00 and gave the company an “underweight” rating in a research report on Monday, March 25th. Finally, JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $175.00 to $190.00 and gave the company a “neutral” rating in a report on Wednesday, March 27th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $187.00.

Shares of EW opened at $178.89 on Wednesday. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.17. Edwards Lifesciences Corp has a 12 month low of $134.38 and a 12 month high of $197.86. The company has a market capitalization of $37.15 billion, a price-to-earnings ratio of 38.06, a price-to-earnings-growth ratio of 2.28 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.23 by $0.09. The firm had revenue of $993.00 million for the quarter, compared to analyst estimates of $989.87 million. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The business’s revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.22 earnings per share. Research analysts anticipate that Edwards Lifesciences Corp will post 5.28 earnings per share for the current year.

In other Edwards Lifesciences news, VP Robert W.A. Sellers sold 821 shares of the business’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $175.36, for a total transaction of $143,970.56. Following the transaction, the vice president now owns 14,176 shares of the company’s stock, valued at $2,485,903.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Catherine M. Szyman sold 1,474 shares of the business’s stock in a transaction on Thursday, February 21st. The stock was sold at an average price of $176.34, for a total value of $259,925.16. Following the transaction, the vice president now directly owns 15,905 shares in the company, valued at approximately $2,804,687.70. The disclosure for this sale can be found here. Insiders sold 146,937 shares of company stock worth $25,927,332 over the last ninety days. Corporate insiders own 1.63% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.mareainformativa.com/news/2019/05/15/edwards-lifesciences-corp-ew-shares-bought-by-toronto-dominion-bank.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: What are gap-down stocks?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.